A Phase I Study of Subcutaneous Ocaratuzumab (Fab- and Fc-engineered Anti-CD20 Monoclonal Antibody) in Patients With Previously Treated CD20+ B-Cell Malignancies

Trial Profile

A Phase I Study of Subcutaneous Ocaratuzumab (Fab- and Fc-engineered Anti-CD20 Monoclonal Antibody) in Patients With Previously Treated CD20+ B-Cell Malignancies

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2014

At a glance

  • Drugs Ocaratuzumab (Primary)
  • Indications B cell lymphoma; B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors MENTRIK Biotech
  • Most Recent Events

    • 28 Feb 2014 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 28 Feb 2014 Planned initiation date changed from 1 Aug 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 27 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top